The goal of the Indiana-ICMIC planning grant is to foster collaboration between scientist involved in the development and application of in-vivo and in-vitro imaging methodologies with investigators involved in the extensive basic science and clinical cancer research programs of the Indiana University Cancer Center (IUCC). This pre-ICMIC planning grant program provides a unique opportunity to facilitate the integration of many currently disparate cancer research and imaging programs within our institution. While the overall goal of this program is to develop and apply non-invasive in-vivo imaging methods that are suitable for use in cancer patients, we feel that current state-of-the-art in-vivo imaging techniques cannot provide all of the important information available through imaging technologies at the present time. Therefore, we have chosen an approach in which we will utilize both in-vivo and in-vitro imaging methods to aid in the study and development of cancer therapies. Our overall hypothesis is that in-vivo imaging applications that elucidate unique physiologic mechanisms in neoplastic disease will serve as important surrogate markers for the presence of cancer and its response to therapy. The research specific aims of this program will be: 1) Identification and development of tracers and/or contrast agents to monitor gene expression and cellular physiology, 2) Development of novel in vitro and in vivo imaging methodologies for the study of cellular and molecular processes, and 3) Application of in vitro and in vivo imaging methods to monitor tumor cellular physiology and gene expression. The primary focus of this planning grant will be the development of 5-6 cancer imaging research programs that will form the basis of a comprehensive ICMIC application within the next 2-3 years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory Grants (P20)
Project #
1P20CA086350-01
Application #
6132995
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J2))
Program Officer
Menkens, Anne E
Project Start
2000-05-01
Project End
2003-04-30
Budget Start
2000-05-01
Budget End
2001-04-30
Support Year
1
Fiscal Year
2000
Total Cost
$399,999
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
005436803
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Shanmugam, Rajasubramaniam; Jayaprakasan, Vetrichelvan; Gokmen-Polar, Yesim et al. (2006) Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. Prostate 66:1498-511
Miller, Kathy D; Miller, Michael; Mehrotra, Sanjana et al. (2006) A physiologic imaging pilot study of breast cancer treated with AZD2171. Clin Cancer Res 12:281-8
Liu, Xuan; Wang, Ji-Quan; Zheng, Qi-Huang (2005) Lipophilicity coefficients of potential tumor imaging agents, positron-labeled O(6)-benzylguanine derivatives. Biomed Chromatogr 19:379-84
Wang, Ji-Quan; Fei, Xiangshu; Gardner, Thomas A et al. (2005) Synthesis of 2-amino-6-(4-[11C]methoxyphenylthio)-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl) ester as a novel potential PET gene reporter probe for HBV and HSV-tk in cancers. Bioorg Med Chem 13:549-56
Li, Xiong; Zhang, Jie; Gao, Huanling et al. (2005) Transcriptional targeting modalities in breast cancer gene therapy using adenovirus vectors controlled by alpha-lactalbumin promoter. Mol Cancer Ther 4:1850-9
Fei, Xiangshu; Zheng, Qi-Huang; Wang, Ji-Quan et al. (2004) Synthesis, biodistribution and micro-PET imaging of radiolabeled antimitotic agent T138067 analogues. Bioorg Med Chem Lett 14:1247-51
Fei, Xiangshu; Wang, Ji-Quan; Miller, Kathy D et al. (2004) Synthesis of [18F]Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers. Nucl Med Biol 31:1033-41
Zheng, Qi Huang; Fei, Xiangshu; Liu, Xuan et al. (2004) Comparative studies of potential cancer biomarkers carbon-11 labeled MMP inhibitors (S)-2-(4'-[11C]methoxybiphenyl-4-sulfonylamino)-3-methylbutyric acid and N-hydroxy-(R)-2-[[(4'-[11C]methoxyphenyl)sulfonyl]benzylamino]-3-methylbutanamide. Nucl Med Biol 31:77-85
Zheng, Qi-Huang; Gardner, Thomas A; Raikwar, Sudhanshu et al. (2004) [11C]Choline as a PET biomarker for assessment of prostate cancer tumor models. Bioorg Med Chem 12:2887-93
Liu, Xuan; Zheng, Qi-Huang; Fei, Xiangshu et al. (2003) Synthesis and preliminary biological evaluation of 6-O-[11C]-[(methoxymethyl)benzyl]guanines, new potential PET breast cancer imaging agents for the DNA repair protein AGT. Bioorg Med Chem Lett 13:641-4

Showing the most recent 10 out of 17 publications